The anogenital human papillomavirus (HPV) is estimated to be the most commonly
occurring sexually transmitted infection in the US. Comprehensive estimates of the annual …

Abstract Current management of Cervical Intraepithelial Neoplasia (CIN), caused by high-
risk human papillomavirus (hr-HPV), is based on surveillance and surgical therapy …

Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

ContextEvery year approximately 2 million US women are diagnosed as having a cervical
cytological result of atypical squamous cells of undetermined significance (ASC-US) …

OBJECTIVE: To evaluate the cost-effectiveness of human papillomavirus (HPV) DNA testing
as a primary screening test in combination with cervical cytology in women aged 30 years or …

Background The availability of human papillomavirus (HPV) DNA testing and vaccination
against HPV types 16 and 18 (HPV-16, 18) motivates questions about the cost-effectiveness …

Objective To determine the costs and health effects of interventions to combat breast,
cervical, and colorectal cancers in order to guide resource allocation decisions in …

OBJECTIVE: The purpose of this study was to examine the health care costs of cervical
human papillomavirus–related disease in a US health care setting. STUDY DESIGN: We …

Background: Studies suggest that cervical cancer screening practice in the United States is
inefficient. The cost and health implications of nonadherence in the screening process …

Importance Many cervical cancer screening strategies are now recommended in the United
States, but the benefits, harms, and costs of each option are unclear. Objective To estimate …